September 27, 2006 -- Today saw the announcement that the FDA approved Infliximab (Remicade) for severe adult psoriasis, a condition with patchy raised skin lesions due to inflammation. The drug is already approved for psoriatic arthritis, as well as rheumatoid arthritis and Crohn’s disease. In 2005, Remicade produced US sales of $2.5 billion for Johnson & Johnson, plus another $1 billion for Schering-Plough in ex-US revenue. We take a closer look at one of the most successful biologicals in the auto-immune disease market today...
